Christian Doppler Laboratory for Production of Next-Level Biopharmaceuticals in E. coli, Department of Biotechnology, BOKU University, Institute of Bioprocess Science and Engineering, Vienna, Austria.
Biopharma Austria, Process Science, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, Vienna, Austria.
Sci Rep. 2024 Oct 25;14(1):25375. doi: 10.1038/s41598-024-73162-9.
Protein engineering with non-canonical amino acids (ncAAs) holds great promises for diverse applications, however, there are still limitations in the implementation of this technology at manufacturing scale. The know-how to efficiently produce ncAA-incorporated proteins in a scalable manner is still very limited. In the present study, we incorporated the ncAA N-[(2-azidoethoxy)carbonyl]-L-lysine (Azk) into an antigen binding fragment (Fab) in Escherichia coli. We used the orthogonal pyrrolysyl-tRNA synthetase/suppressor tRNA pair from Methanosarcina mazei to incorporate Azk site-specifically. We characterized Azk uptake and Fab production at bench-scale under different fermentation conditions, varying timing and mode of Azk addition, Azk-to-cell ratio and induction time. Our results indicate that Azk uptake is comparatively efficient in the batch phase. We discovered that the time between Azk uptake and inducing its incorporation into the Fab must be kept short, which suggests that intracellular Azk is consumed and/or degraded. The results obtained in this study are an important step towards the development of efficient production methods for Azk-incorporated proteins in E. coli. The developed process is scalable and provides excellent yields of 2.95 mg functionalized Fab per g CDM, which corresponds to 80% of yield obtained with the wild type Fab. We also identified the cellular uptake of Azk being dependent on the physiological state of the cell as a potential bottleneck in production.
利用非天然氨基酸(ncAAs)进行蛋白质工程在多个应用领域具有广阔的前景,然而,在制造规模上实施这项技术仍然存在限制。高效生产可扩展 ncAA 掺入蛋白的技术诀窍仍然非常有限。在本研究中,我们在大肠杆菌中掺入非天然氨基酸 N-[(2-叠氮乙氧基)羰基]-L-赖氨酸(Azk)到抗原结合片段(Fab)中。我们使用来自 Methanosarcina mazei 的正交吡咯赖氨酸-tRNA 合成酶/抑制 tRNA 对来特异性掺入 Azk。我们在不同发酵条件下,在台架规模下,通过改变 Azk 添加的时间和方式、Azk-细胞比和诱导时间,对 Azk 摄取和 Fab 生产进行了表征。结果表明,在分批培养阶段,Azk 摄取效率相对较高。我们发现,必须保持 Azk 摄取和诱导其掺入 Fab 之间的时间短,这表明细胞内的 Azk 被消耗和/或降解。本研究的结果是开发在大肠杆菌中高效生产 Azk 掺入蛋白的方法的重要一步。所开发的工艺具有可扩展性,可提供 2.95mg 功能化 Fab/gCDM 的出色产率,这相当于野生型 Fab 产率的 80%。我们还发现 Azk 的细胞摄取依赖于细胞的生理状态,这可能是生产中的一个潜在瓶颈。